Our Pipeline

Targovax has differentiated assets with orphan indications

Indication
Program
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
Mesothelioma*
Melanoma
Colorectal Cancer
Ovarian and Colorectal Cancer*
Prostate Cancer
Discovery

A broad and diversified pipeline in multiple indications
Low price tag on go/no-go decisions
*Orphan Drug Designations (ODD)

Targovax is an innovation driven specialist in immuno-oncology.

Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapy treatments for cancer patients.
Targovax is developing two highly targeted approaches to cancer immunotherapy:

  • the ONCOS  platform, a virus-based oncolytic immunotherapy based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumor

  • the TG platform are neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of RAS

Both treatment approaches activate the patient’s own immune system to fight the cancer.

The Targovax pipeline, built on a robust knowledge of the immunotherapy area and unique technologies, includes a number of product candidates targeted at a wide range of cancer types. Its lead candidate,  ONCOS-102  has successfully completed Phase I clinical trial and are currently being tested in further early-stage clinical trial (Phase I and/or Phase II. TG02, the company’s second generation cancer vaccine, is being investigated the first time in a clinical phase Ib study in colorectal cancer.

Adenoviruses and Cancer

Targovax is also developing a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.

This cancer immunotherapeutic technology has a targeted mechanism of action making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-targeted anti-tumor immune response.

RAS mutations and Cancer

Targovax is developing a highly targeted immunotherapy for patients with RAS-mutated tumors - the most frequently mutated oncogene in cancer, with no approved therapies. Mutation of RAS disrupts normal cell division signalling, and occurs early in the transformation from a normal to a cancer cell.

RAS mutations are a key driver of cancer progression and treatment resistance. They are found in 20 - 30% of all cancers1, over 90% of pancreatic cancers2, 50% of colorectal cancers3, between 20 and 30% of non-small cell lung cancers4 and between 20 and 30% of malignant melanomas1.

Few treatment options are available for patients with RAS mutations and of limited efficacy, highlighting the significant unmet medical need for these patients.

References:

  1. Fernandez-Medarde, A. and Santos, E.; RAS in Cancer and Developmental Diseases; Genes & Cancer. 2011;2(3):344–358
  2. Raphael B.J. et al; Integrated genomic characterization of pancreatic ductal adenocarcinoma; Cancer Cell 32, 185-203, August 14, 2017
  3. Van Cutsem, E. et al; Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer; J Clin Oncol. 2015; 33(7):692-700
  4. D’Arcangelo, M. and Cappuzzo, F.; K-RAS Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value; International Scholarly Research Network, ISRN Molecular Biology, Volume 2012, Article ID 837306, 8p.